v3.26.1
Shareholders’ Deficit (Tables)
 12 Months Ended
Dec. 31, 2025
Shareholders’ Deficit [Line Items]  
Schedule of Obligated to Issue Shares

As of December 31, 2025 and 2024, the Company was obligated to issue the following shares:

 

   December 31, 2025   December 31, 2024 
   Amount   Shares   Amount   Shares 
Shares issuable to employees and consultants  $49,498    9,931   $81,632    14,305 
Shares issuable to independent directors   
–
    
–
    80,000    16,327 
Private placement issuable   11,851    12,121    
–
    
–
 
   $61,349    22,052   $161,632    30,632 
Schedule of Financial Statements with Respect to the EIPs

Amounts recognized in the financial statements with respect to the EIPs in the years ended December 31, 2025 and 2024 were as follows:

 

   Year Ended December 31, 
   2025   2024 
Total cost of share-based payment plans during the period  $158,625   $153,186 
Amounts capitalized in deferred equity compensation during period  $
–
   $
–
 
Amounts written off from deferred equity compensation during period  $
–
   $57,147 
Amounts charged against income for amounts previously capitalized  $
–
   $
–
 
Amounts charged against income, before income tax benefit  $158,625   $210,333 
Amount of related income tax benefit recognized in income  $
–
   $
–
 
Stock Warrants [Member]  
Shareholders’ Deficit [Line Items]  
Schedule of Stock Warrants

Transactions involving our stock warrants during the years ended December 31, 2025 and 2024 are summarized as follows:

 

   2025   2024 
       Weighted       Weighted 
       Average       Average 
       Exercise       Exercise 
   Number   Price   Number   Price 
Outstanding at beginning of the period   1,014,932   $16.25    774,146   $20.48 
Granted during the period   69,333   $2.26    302,308   $6.38 
Exercised during the period   
–
   $–    
–
   $– 
Expired during the period   (279,914)  $(12.61)   (61,522)  $(27.84)
Outstanding at end of the period   804,351   $16.31    1,014,932   $16.43 
                     
Exercisable at end of the period   804,351   $16.31    1,014,888   $16.43 
                     
Weighted average remaining life   4.4 years    3.6 years 
Schedule of Company’s Stock Warrants Outstanding

The following table summarizes information about the Company’s stock warrants outstanding as of December 31, 2025:

 

Warrants Outstanding   Warrants Exercisable 
        Weighted-             
        Average   Weighted-       Weighted- 
        Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life (years)   Price   Exercisable   Price 
$0.02 to 10.00    395,973    7.9   $4.94    395,973   $4.94 
$10.01 to 25.00    184,434    2.2   $15.00    184,434   $15.00 
$25.01 to 50.00    194,334    0.1   $32.91    194,334   $32.91 
$50.01 to 105.00    29,610    0.5   $67.57    29,610   $67.57 
$0.02 to 105.00    804,351    4.4   $16.31    804,351   $16.31 
Schedule of Fair Value of Warrants Range of Assumptions The fair value of the warrants was calculated using the following range of assumptions:
   2025   2024 
Pricing model utilized   Binomial Lattice    Binomial Lattice 
Risk free rate range   3.70% to 4.24%    3.65% to 4.69% 
Expected life range (in years)   10.00 years    5.00 to 10.00 years 
Volatility range   159.13% to 175.32%    139.73% to 173.25% 
Dividend yield   0.00%    0.00% 
Expected forfeiture   44.00%    33.00% 
Stock Options [Member]  
Shareholders’ Deficit [Line Items]  
Schedule of Stock Option Activity The following table summarizes stock option activity as of and for the years ended December 31, 2025 and 2024:
   2025   2024 
       Weighted       Weighted 
       Average       Average 
       Exercise       Exercise 
Stock options  Number   Price   Number   Price 
Outstanding at beginning of period   61,579   $6.94    50,937   $15.57 
Granted during the period   75,000   $2.20    48,055   $5.84 
Exercised during the period   
–
   $
–
    
–
   $
–
 
Forfeited during the period   (788)  $(17.33)   (37,413)  $(17.48)
Outstanding at end of period   135,791   $4.26    61,579   $6.94 
                     
Options exercisable at period-end   102,791   $4.60    48,074   $6.94 
Schedule of Fair Value of Options Granted The fair value of options granted for the years ended December 31, 2025 and 2024 was calculated using the following range of assumptions:
   2025   2024 
Pricing model utilized   
Binomial Lattice
    Binomial Lattice 
Risk free rate range   4.26%    4.20% to 4.23% 
Expected life range (in years)   10.00 years    10.00 years 
Volatility range   172.20%    173.09% to 173.25% 
Dividend yield   0.00%    0.00% 
Expected forfeiture   30.00%    30.00% 
Schedule of Stock Grant Activity

The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the years ended December 31, 2025 and 2024:

 

   2025   2024 
       Weighted       Weighted 
       Average       Average 
       Grant Date       Grant Date 
Stock options  Shares   Fair Value   Shares   Fair Value 
Nonvested options at beginning of period   13,500   $4.75    10,731   $6.14 
Granted   75,000   $1.53    48,049   $4.09 
Vested   (55,500)  $(1.89)   (37,322)  $(4.11)
Forfeited   
–
   $
–
    (7,958)  $(5.62)
Nonvested options at end of period   33,000   $2.23    13,500   $4.75 
Stock Grants [Member]  
Shareholders’ Deficit [Line Items]  
Schedule of Stock Grant Activity The following table summarizes stock grant activity as of and for the years ended December 31, 2025 and 2024:
   2025   2024 
       Weighted       Weighted 
       Average       Average 
       Grant Date       Grant Date 
Stock Grants  Shares   Fair Value   Shares   Fair Value 
Nonvested grants at beginning of period   
–
   $
–
    14,845   $5.19 
Granted   369,541   $1.43    
–
   $
–
 
Vested   (23,291)  $(1.47)   (12,295)  $(4.93)
Forfeited   
–
   $
–
    (2,550)  $(6.43)
Nonvested grants at end of period   346,250   $1.43    
–
   $
–